



## **P R E S S R E L E A S E**

Lelystad, 3 November 2005

### **Fornix BioSciences upgrades 2005 sales and profit forecast**

- **2005 net profit growth forecast adjusted upwards from 18–22% to at least 35%**
- **Sales growth forecast up from 5% to 10%**
- **Upgraded profit forecast reflects results of Allergy and Trading Divisions exceeding expectations in recent months**
- **Forecast negative result of Theranostics division unchanged**

**Biopharmaceutical company Fornix BioSciences (Euronext: AFORBI) has upgraded its net profit forecast for 2005 to at least €8.9 million, an increase of at least 35% on the 2004 figure of €6.6 million. On 5 July of this year, Fornix had already revised its forecast of profit growth from 10% to 18–22% (based on IFRS) compared with 2004. The sales growth forecast has also been upgraded, from 5% at the beginning of the year to 10% now, i.e. from €76.6 million in 2004 to at least €84.3 million in 2005.**

These revised figures mainly reflect the performance of the Allergy and Trading Divisions, which has exceeded expectations by a significant margin in recent months. This rising trend, which also underpinned July's updated forecast, has been sustained. Barring unforeseen circumstances, Fornix expects to at least maintain this improved level of performance for the rest of the financial year.

#### **Theranostics**

Fornix is standing by its July forecast that, with EBIT of just over €1 million negative, the Theranostics Division would end 2005 with a substantially reduced loss compared with the 2004 figure of €1.6 million.

### **Results of STARDROP study**

As indicated in the interim report published on 1 August 2005, the company is still awaiting the full results of the STARDROP trials. Until it has evaluated the full report, Fornix will not be in a position to assess the contribution which these trials can make to the application for registration of Oralgen® Grass Pollen.

A more detailed review of Fornix's activities and results in 2005 will be given in a press release to be published before start of trading on 24 January 2006.

Note for editors. **For further information, call:**

C.L. Bergman, CEO Fornix BioSciences N.V.

Tel. +31 6 538 11 747 / +31 320 26 77 99

[www.fornix.nl](http://www.fornix.nl)

### **Profile of Fornix BioSciences N.V.**

Fornix BioSciences N.V., which has its headquarters in Lelystad (Netherlands), has four divisions which specialise in biotechnological research, production, marketing and sale of diagnostic and therapeutic anti-allergy products, medical aids and microbiological products and trading in patented pharmaceuticals. The Research & Development Division is largely funded by the positive cash flow generated by the profit-making divisions.

The four divisions work through the operating companies ARTU Biologicals, Fisher Farma, Fornix BioTech Holding and Fornix Theranostics. ARTU Biologicals Europe specialises in the production and sale of anti-allergy products and medical aids, Fisher Farma trades in patented pharmaceuticals, Fornix BioTech Holding engages in biotechnological research and Fornix Theranostics is active in diagnostic products. Fornix BioSciences N.V. shares are listed on the Official Market of the Euronext stock exchange in Amsterdam.